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ABSTRACT
We have previously reported on the ex vivo generation of cytotoxic effector cells, termed cytokine-induced
killer (CIK) cells, that have both in vitro and in vivo antitumor activity in murine models. We now report on
our efforts for the large-scale expansion of CIK cells and also present preliminary results from a phase I clinical
trial. Nine patients with advanced Hodgkin disease (n  7) and non-Hodgkin lymphoma (n  2), all of whom
had relapsed after an autologous transplantation, were treated with escalating doses of CIK cells (3 patients at
each dose level of 1  109, 5  109, or 1  1010 cells). The CIK cells were produced by culturing unselected
cells from steady-state apheresis products with interferon , OKT3, and interleukin 2. After 21 days in culture,
with the addition of fresh media and interleukin 2 every 3 to 4 days, the median culture was 97% viable (range,
61%-100%), 98% CD3 (range, 66%-99%), 76% CD8 (range, 27%-96%), 23% CD4 (range, 6%-78%), 20%
CD3CD56 (range, 8%-58%), and <1% CD1656 (range, 0.2%-7.7%). The CD3CD56 cells have
previously been shown to exhibit the most cytotoxic activity. The absolute number of CD3CD56 cells
typically expanded 290-fold (range, 3- to 4000-fold) under these culture conditions. In vitro cytotoxic activity
was measured against a human B-cell tumor line (OCI-Ly8). At a 40:1 effector-target cell ratio, CIK cells killed
32% (range, 2%-69%) of the target cells. A total of 21 infusions were administered to 9 patients. The number
of CIK cells infused ranged from 1.0  109 to 1.0  1010 per treatment. Toxicity was minimal, and there were
no immediate adverse reactions to the infusions. Two patients had partial responses, and 2 patients had
stabilization of disease: 1 for more than 18 months. Considering that these were heavily pretreated patients
with advanced hematologic malignancies, we believe that CIK cells expanded in this fashion may have utility
for the treatment of high-risk patients with evidence of minimal residual disease after autologous transplan-
tation.
© 2005 American Society for Blood and Marrow Transplantation
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Relapse is a major cause of treatment failure after
utologous hematopoietic cell transplantation. After
ransplantation, most patients achieve a state of min-
mal residual disease in which alternative treatment
trategies such as immunotherapeutic interventions
ay hold promise. A variety of strategies have been
xplored in an effort to activate autologous effector
ells to recognize and kill tumor targets. Interleukin
IL)–2–activated natural killer (NK) cells or lympho-
ine-activated killer (LAK) cells [1] are produced by c
B&MThort-term culture of lymphocytes in the presence of
igh concentrations of IL-2. These cells have the
ell-surface phenotype of CD3CD56. The clinical
pplication of these cytotoxic effector cells has been
imited by their relatively low antitumor cytotoxic
ctivity and the difﬁculty encountered in obtaining
linically relevant cell numbers [2,3]. In addition,
AK cells require IL-2 for biological activity; this has
een associated with considerable toxicity [4] that
omplicates interpretation of potential efﬁcacy.
Tumor-inﬁltrating lymphocytes (TILs), which are
ultured and expanded from tumor tissue, are another
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1trategy. These cells are CD8 and recognize tumors
hrough T-cell receptor (TCR)–mediated mecha-
isms. TILs are challenging to expand and may not be
ecoverable from patients who have minimal tumor
ulk. After infusion of TILs, tumor responses have
een noted in some patients [5]. An alternative strat-
gy has been to expand peripheral blood mononuclear
ells in the presence of interferon (IFN)–, IL-2, and
monoclonal antibody against the CD3 surface anti-
en (OKT3). We have characterized the resulting
ffector cell populations that share functional and
henotypic properties of both T cells and NK cells.
hese cells have been termed cytokine-induced killer
CIK) cells. CIK cells exhibit non–major histocompat-
bility complex–restricted killing of tumor cell targets
oth in vitro and in vivo [6,7]. The cell population
ith the greatest cytotoxic activity in these cultures
xpresses both the CD3 marker characteristic of
cells and the CD56 marker characteristic of NK
ells. CIK cells are predominantly CD8 and TCR-
/. CD3CD56 T cells circulate in the peripheral
lood and have cytotoxic activity [8]. CIK cells are
nique in that they have phenotypic and functional
ttributes of both T cells and NK cells. They are
unctionally like NK cells in that they do not require
riming, yet they are also like T cells in that they
xpress CD3 and are rapidly expandable in culture.
CIK cells are capable of lysing a variety of tumor
ell lines and fresh tumor isolates in vitro and have
reater activity in vivo than LAK cells. CIK cells can
e expanded from patients with a variety of hemato-
ogic malignancies and are capable of lysing fresh
utologous myeloid leukemias [9,10]. CIK cells do not
equire exogenous administration of IL-2 for in vivo
ctivity. In one study, approximately 40% to 50% of
everely compromised immunodeﬁcient mice injected
ith CIK cells after they were challenged with a B-
ymphoma cell line (SU-DHL4) became long-term
urvivors, compared with none of the control animals
nd none of the animals treated with LAK cells [7]. In
nother study, expanded CIK cells from patients with
hronic myeloid leukemia (CML) suppressed autolo-
ous CML colony growth in vitro but did not inhibit
he growth of normal hematopoietic colonies. CIK
ultures were completely Philadelphia negative after 4
eeks in 12 of 13 cultures. [11]. Autologous CIK cells
ere capable of inhibiting CML growth in severely
ompromised immunodeﬁcient mice engrafted with
ML. [11] The in vivo activity of CIK cells against
eLa cells injected into severely compromised immu-
odeﬁcient mice was measured by using a novel bio-
uminescence assay to visualize tumor growth [12]
ice receiving 1 or 2 treatments of 1  107 CIK cells
howed statistically signiﬁcant reductions in tumor
ignal compared with control animals.
A similar population of murine cells is readily
xpandable from bone marrow and spleen. Murine c
82ells similarly express CD3, TCR, and the NK cell
arkers NK1.1 and DX5 [13]. Murine cells were
apable of controlling the syngeneic tumor growth of
cl1 lymphoma cells. It is interesting to note that the
xpanded murine cells had a markedly attenuated ca-
acity for graft-versus-host disease (GVHD) induc-
ion related to the production of IFN- [13].
CIK cells function through primarily perforin-
ediated mechanisms [14]. CIK cells do not express
D16 (Fc receptor) and therefore do not kill targets
ia antibody-dependent cellular cytotoxicity. A cyto-
lasmic granule release mechanism is involved, and
here are at least 2 distinct activation pathways that
an cause degranulation, because anti-CD3–mediated
egranulation is inhibited by immunosuppressive
gents (cyclosporin A and FK506), whereas target
ell–stimulated degranulation is not [15]. Both forms
f activation are known to cause the release of per-
orin, a pore-forming serine esterase enzyme. The
ytotoxic effects of CIK cells can be blocked by anti-
odies against the intercellular adhesion molecules
FA-1 and intercellular adhesion molecule 1 [6]. More
ecently, a major role of NKG2D engagement has
een demonstrated in which blocking monoclonal an-
ibodies and small interfering RNA studies inhibiting
KG2D expression abrogated cytotoxicity [16].
On the basis of these in vitro and in vivo antitumor
iological activities, a phase I clinical trial was per-
ormed to test the safety and feasibility of infusing
utologous CIK cells into patients with relapsed
odgkin disease (HD) and non-Hodgkin lymphoma
NHL). The purpose of this trial was 2-fold: (1) to test
he feasibility of culturing clinically relevant numbers
f CIK cells in a clinical laboratory setting and (2) to
etermine the toxicity associated with infusing CIK
ells into cancer patients.
ATERIALS AND METHODS
linical Trial Design
This trial was designed as a dose-escalation study.
he study followed a dose-escalation format of 3 CIK
ell dose levels with 3 patients at each dose level. Dose
scalation was allowed if there were no grade III or IV
oxicities at a given dose. The study was initiated at
 109 cells per infusion, and the dose was escalated
o 5  109 and ﬁnally to 1  1010 cells per infusion.
p to 3 infusions were allowed, assuming that there
as no toxicity and no evidence of disease progression.
he dose infused in subsequent infusions was at the
ose level open at that particular time. Eligible pa-
ients had either B-cell NHL or HD and had relapsed
fter conventional therapy. All patients had undergone
utologous hematopoietic cell transplantation and had
elapsed. A total of 9 patients were treated, the clinical
haracteristics of which are shown in Table 1.
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Phase I Trial of CIK Cells
BCIK cells were generated by culturing a steady-
tate apheresis product for 21 days, as described be-
ow. The cell dose infused was deﬁned by protocol and
as based on the total viable cell number. Patients
ere followed up for signs of toxicity (as deﬁned by
orld Health Organization toxicity criteria) immedi-
tely after and for 2 months after infusion. Although
he purpose of this trial was primarily to determine
easibility and safety, the patients were also followed
p with regular physical examinations, biopsies, and
adiographic studies to document objective tumor
esponses.
Only patients with pathologically conﬁrmed re-
apsed HD or NHL of B-cell origin with no alterna-
ive curative potential were eligible to be enrolled into
his study. The patients were required to be65 years
f age and to have signed an informed consent form
ccording to Stanford University Institutional Review
oard guidelines. They were not to have received any
hemotherapy for 3 weeks before the start of apheresis.
heir leukocyte count had to be at least 3000/	L, and
heir platelet count had to be at least 100 000/	L
efore apheresis. Patients required evidence of ade-
uate renal and hepatic function and a Karnofsky
erformance score of 
70 before being admitted into
his study.
IK Cell Expansion
Starting with a steady-state apheresis product
Cobe Spectra; Gambro BCT, Lakewood, CO), un-
ractionated cells were cultured overnight at 2  106
otal nucleated cells per milliliter in Aim V (Gibco
RL, Grand Island, NY) with 10% autologous plasma
collected at the time of apheresis) and IFN- 1000
/mL (InterMune Pharmaceuticals, Palo Alto, CA).
he Aim V media contained gentamycin 10 	g/mL
nd streptomycin 50 	g/mL. To maintain a closed
ystem, the cells were incubated in Lifecell tissue cul-
ure bags (Baxter Oncology, Deerﬁeld, IL). Most of the
ultures were initiated with a total of 2.4 109 cells in
total of 1200 mL of media divided equally among 6
able 1. Clinical Responses
Patient No.* Age (y) Sex
1 28 M
2 67 M
3 53 M
4 45 M
5 25 M
6 23 M
7 30 F
8 32 M
9 30 F
D, indicates Hodgkin disease; NHL, non-Hodgkin lymphoma; N
Nine patients were treated with a total of 21 CIK infusions.
Patients received 1, 2, or 3 separate infusions approximately 2 moulture bags. After 18 to 24 hours in culture at 37°C
B&MTnd 5% CO2, OKT3 50 ng/mL (Ortho Biotech, Rari-
an, NJ) and IL-2 300 U/mL (Chiron, Emeryville,
A) were added. IL-2 was added every 3 to 4 days,
egardless of cell concentration, and fresh medium
as added as needed to maintain a cell concentration
f 1 to 4  106/mL. A sterile connecting device
Terumo, Somerset, NJ) was used to attach tubing as
eeded for cytokine and media additions.
Each of the individual culture bags was sampled on
ay 19 for sterility testing, and then, on day 21, the
ells were harvested and washed twice with a COBE
991 (Gambro BCT) cell washer. The cells were re-
uspended to approximately 300 mL in Normosol
Hospira, Lake Forest, IL) and 1% human serum
lbumin. Additional samples were removed for steril-
ty testing, phenotypic analysis, and cytotoxicity as-
ays, and the cells were infused within 60 minutes of
arvesting. The cell dose was deﬁned by the protocol
nd was based on the total viable cell number.
uality Control Assays
Cell dose criteria were based on the total viable
ell number, as determined by manual hemacytometer
ell counts and trypan blue dye exclusion. Each cul-
ure bag was tested for sterility 2 days before pooling
day 19). Small aliquots (1 mL) were cultured for
erobic bacterial and fungal cultures. Preliminary re-
orts were generated at 24 hours so that only the
ulture bags that showed no growth were pooled to-
ether for harvest. Samples from the pooled product
ere also submitted for sterility testing (5-day cul-
ure), but results were not available before infusion.
Phenotypic analysis of the preculture and postcul-
ure cell populations was achieved by using ﬂuorescein-
abeled monoclonal antibodies to CD3 and CD16 and
hycoerythrin-labeled antibodies to CD56, CD4, and
D8 (Becton Dickinson, San Jose, CA). Cells were
ncubated with antibodies for 30 minutes at 4°C. Ex-
ess antibody was removed, and the stained cells were
nalyzed with a FACScan instrument (Becton Dick-
nson).
iagnosis Dose ( 109)† Response
HD 1,1 NR
HD 1,5,5 PR
HD 1,5 PR
NHL 5,5 NR
NHL 5,5,5 SD
HD 5,10,10 NR
HD 10,10 NR
HD 10,10,10 SD
HD 10 NR
response; PR, partial response; SD, stable disease.
art at the doses indicated.D
R, noIn vitro cytotoxicity assays were performed on the
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1ay of infusion by using a chromium 51 (51Cr) release
ssay. Target cells (OCI-Ly8) were labeled with 51Cr
Dupont-NEN, Boston, MA) by incubating 2  106
ells per milliliter in RPMI with 300 	Ci of 51Cr for
hours at 37°C. The labeled cells were washed 3
imes with phosphate-buffered saline and then resus-
ended to 2  105 cells per milliliter in RPMI/10%
etal calf serum. A total of 2  104 labeled cells
0.1 mL) were placed into the appropriate number of
6-well microtiter plate wells. Effector cells were
dded at a 40:1 effector-target ratio and incubated at
7°C for 4 hours. At the completion of the assay, an
liquot (75 	L) of the supernatant was counted with a
amma counter. The percentage of speciﬁc 51Cr re-
ease was calculated according to the following equa-
ion:
specific release

(CPM test) (CPM spontaneous release)
(CPM maximal release)
 (CPM spontaneous release)
 100
pontaneous release was obtained by incubating cells
n media alone, and maximal release was obtained after
reatment with 2% NP-40.
linical Response Criteria
For the purposes of this study, response criteria
ere as follows: complete response indicated complete
esolution of all clinical and radiographic signs of
isease; partial response indicated measurable radio-
raphic tumor reduction; stable disease indicated nei-
her reduction nor progression of disease; and no
esponse indicated continue progression of disease.
ESULTS
The patients’ median age was 30 years (range,
3-67 years). Seven of the 9 patients treated had HD,
nd 2 patients had NHL. Five of the 7 HD patients
ere male, as were both of the NHL patients. All
atients had experienced treatment failure with prior
herapies, including autologous hematopoietic cell
ransplantation. The target CIK cell dose was
chieved in 19 of 21 cultures. Both cultures that fell
hort of target cell numbers were from the highest-
ose cohort. Overall, a median 7-fold total cell expan-
ion was observed during 21 days in culture (range, 1-
o 11-fold), meaning that most often excess cells were
roduced. Typically, the viable cell number would
ecline slightly during the ﬁrst few days in culture but
ould increase rapidly after 5 to 7 days. The culture
ags were usually split into 2 bags on day 12 to 14 to
aintain the desired cell concentration. The median
ostculture viability was 97.5%.A total of 197 culture bags were used (including c
84ubcultures) to produce enough CIK cells for the 21
nfusions. On 4 occasions (2%), a positive sterility test
btained from the day 19 (or day 20) sample affected
he pooling decision. Three of these 4 occurrences
ould have been false positives, on the basis of the
rowth pattern observed and of the lack of macro-
copic contamination evidence in the culture itself;
owever, none of the bags was pooled for infusion.
nly once did a culture show growth after the 24-
our test period and, therefore, after infusion.
Results from phenotypic analysis of the CIK cul-
ures are presented in Figure 1. These cultures started
ith a typical CD3 T-cell percentage of approxi-
ately 30%, whereas the starting CD3CD56 per-
entage was1%. After the 21-day culture period, the
ean CD3 percentage was 95.3% (range, 66.2%-
9.6%), and only 4 of 21 cultures contained 95%
D3 cells. On average, 67% of the CD3 cells were
D8, and 30% were CD4. The median percentage
f CD3CD56 cells was 22% (range, 8%-58%). In
ontrast, traditional CD16CD56 NK cells com-
rised only approximately 2% of the postculture cell
opulation.
Expansion of CD3 T cells was measured by ﬂow
ytometry. Figure 2 shows the results for each of the
1 individual cultures, grouped according to patient
umber. The total CD3 number expanded a median
f 24-fold under these culture conditions (range, 2- to
3-fold). Similarly, CD3CD56 cells typically ex-
anded 290-fold (Figure 3), but there was a large
ariation in the level of expansion observed (range,
- to 4000-fold). The reason for the variability is
nclear, although it is likely that prior patient treat-
ent played a role, as did the difﬁculty in accurately
easuring such low starting percentages. There was
ess individual patient variability among cultures than
mong patients (Figures 2 and 3).
The CIK cells were tested in a 51Cr release assay
or their in vitro cytotoxicity against a neoplastic B-
igure 1. Phenotypic analysis (mean  SD) of CIK cultures before
nd after the 21-day culture period. NT indicates not tested.ell line (OCI-Ly8) immediately after their 21-day
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Bulture period. The results are shown in Figure 4. At
40:1 effector-target ratio, the CIK cells typically
illed 32% of the target cells in 4 hours (range, 2%-
9%). Some of the patients’ CIK cells lysed these
arget cells better than other patients’ cells; however,
ultiple cultures from the same patient had similar in
itro cytotoxic activity. Thus, with 1 exception (pa-
ient 8), the variability seems more patient related
han individual culture related.
Minimal infusion-related toxicity was observed.
ne case of asymptomatic mild hypotension occurred
mmediately after infusion, and it was quickly re-
olved. One patient developed fever (38°C), and 1
atient experienced thrombocytopenia that was
hought to be related to disease progression rather
han to treatment.
Although clinical response was only a secondary
nd point for this particular study, those results are
hown in Table 1. Of the 9 patients treated, 2 patients
ad partial responses (measurable radiographically
ocumented tumor reduction), and 2 patients had
tabilization of their disease—1 for more than a year.
here was no measurable response in the remaining 5
atients. All clinical responses were transient in this
eavily pretreated cohort of patients with extensive
isease.
ISCUSSION
Autologous hematopoietic cell transplantation has
roven to be an effective therapy for patients with a
ariety of hematologic malignancies. However, a sig-
iﬁcant percentage of patients ultimately relapse even
hough most patients enter a state of minimal residual
isease. Therefore, strategies effective at treating pa-
igure 2. Expansion of CD3 cells during 21 days in culture, as
escribed in Materials and Methods. A total of 21 cultures were
nitiated with steady-state apheresis products from 9 different pa-
ients. Fold expansion  absolute number of CD3 cells at the end
f 21 days in culture/absolute number of CD3 cells at the start of
ulture.ients with minimal disease are likely to improve over- a
B&MTll survival. A variety of treatment strategies have been
xplored, including cytokines [17], activated NK cells
18], and monoclonal antibodies [19].
In this study, we used ex vivo–expanded CIK cells
o evaluate the feasibility and toxicity of this treatment
pproach. CIK cells have several advantage that makes
his cellular product attractive: they are readily ex-
andable from patients with a variety of malignancies
9] and have in vivo activity superior to that of LAK
ells [7], without the need for exogenous administra-
ion of IL-2.[7,11] CIK cells have been well tolerated
n animal models of both human[11,12,20] and mu-
ine[21,22] disease. CIK cells were expanded from
atients with either HD or NHL who had experi-
nced treatment failure with prior autologous trans-
lantation. All patients had extensive and measurable
isease. Cell expansion was similar to that obtained
rom buffy coat samples obtained from healthy donors
7]. Total cell, CD3, and CD3CD56 expansions
ere variable from patient to patient; however, indi-
idual patients had similar growth characteristics from
ulture to culture. Expansion of CD3CD56T cells,
hich have been identiﬁed as the cellular population
ith the greatest in vitro cytotoxicity, was 290-fold
fter 21 days in culture. Most patients reached their
rotocol-deﬁned cell dose, which varied from 1  109
o 1  1010 cells.
Recently we have identiﬁed NKG2D as the major
ell-surface receptor involved in CIK cell–mediated
ytotoxicity because monoclonal antibodies directed
gainst this cell-surface molecule and small interfering
igure 3. Expansion of CD3CD56 cells during 21 days in
ulture, as described in Materials and Methods. Twenty of 21
ultures (from 9 different patients) that were initiated with steady-
tate apheresis products were tested. Fold expansion  absolute
umber of CD3CD56 cells at the end of 21 days in culture/
bsolute number of CD3CD56 cells at the start of culture.
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1NA–containing sequences of the C-terminal portion
f the gene decrease NKG2D expression; both result
n a signiﬁcant reduction in cytotoxic function. Al-
hough CD3CD56 cells have the highest level of
xpression of NKG2D, which increases with in vitro
ulture, CD8, but not CD4, T cells also express
KG2D [16]. It is interesting to note that over time,
pregulation of the adaptor molecule Dap10 corre-
ates with cytotoxic activity. These studies would pre-
ict that tumor cells expressing ligands for NKG2D
ould be the most likely to respond to CIK-mediated
mmunotherapy.
Toxicity was mild after the infusion of 21 cellular
roducts to 9 patients. One patient developed mild
ypotension, which was asymptomatic and responded
o intravenous ﬂuids, and a second patient developed a
ow-grade fever. One additional patient developed
hrombocytopenia several weeks after the ﬁrst CIK
ell infusion; this was thought to be related not to the
reatment, but rather to progression of the underlying
D. Therefore, the CIK cell infusions were well tol-
rated.
Although it was not the intention of the study to
valuate responses, 2 patients had radiographic im-
rovement, with either a reduction or resolution of
ulmonary nodules evaluated by serial computed to-
ographic scanning. An additional 2 patients had sta-
ilization of their disease—in 1 patient for over a year.
here was no clear relationship of disease response to
ell dose; however, all patients who experienced either
partial response or stabilization of disease (patients
, 3, 5, and 8) had in vitro cytotoxic activity above the
edian. The number of patients treated was too small
o reach deﬁnitive conclusions.
A similar population of cells has been evaluated clin-
cally in another study of patients with solid tumors, in
igure 4. Cytotoxicity of expanded CIK cells. CIK cells from each
ulture were tested in 51Cr-release cytotoxicity studies against the
-cell non-Hodgkin lymphoma cell line OCI-Ly8, as described in
aterials and Methods. Results are shown for an effector-target
atio of 40:1 for each culture.hom minimal toxicity was also observed [23]. This
86arger randomized study evaluated cells derived from
atients with hepatocellular carcinoma after surgical re-
ection expanded in a similar fashion. It is interesting to
ote that the patients who received the cells had a sta-
istically signiﬁcant reduction in postsurgical disease re-
urrence [24].
A similar population of murine CIK cells that are
erived by identical culture conditions has also been
valuated in murine models of GVHD and graft ver-
us leukemia. These expanded cells were capable of
raft-versus-leukemia effects with attenuated GVHD
13,14].
In summary, CIK cells are readily expandable
rom patients after transplantation, and cells sufﬁcient
or clinical application can be obtained in a routine
ashion. After infusion, toxicity was minimal, and pre-
iminary evidence of disease response was observed.
he infusion of CIK cells may be a useful treatment
trategy to attempt to reduce the risk of relapse in
igh-risk patients after autologous transplantation.
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